Karrie Wong

Karrie Wong, PhD is currently Vice President, Head of Cell Therapy at KSQ Therapeutics. Dr. Wong leads the cross-functional development of KSQ’s engineered Tumor Infiltrating Lymphocyte (eTIL) programs as well as discovery research on the next generation of Oncology Cell Therapy. Her team’s research areas include target-discovery screens to enhance cell therapy efficacy and process innovation in TIL therapy manufacture. Prior to KSQ, Dr. Wong led research and development efforts on gene edited allogeneic NK cell therapy at Editas Medicine and IO drug discovery programs across different modalities. at Novartis Biomedical Research. Dr. Wong holds a PhD in Immunology/Regenerative Medicine from the University of Toronto and completed her postdoctoral training at Dana Farber Cancer Institute on cancer vaccine research.